REG - Poolbeg Pharma PLC - Result of upsized oversubscribed BookBuild Offer

Poolbeg PharmaAnnouncement

23/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250523:nRSW8784Ja&default-theme=true

RNS Number : 8784J  Poolbeg Pharma PLC  23 May 2025

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, THE
REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE
TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.

THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS
RELATING TO THE BOOKBUILD OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE
TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING
WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL
PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF
POOLBEG PHARMA PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS
ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN
ONLY BY SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY,
AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR
ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY
SECURITIES OF POOLBEG PHARMA PLC.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.

FOR IMMEDIATE RELEASE.

23 May 2025

 

Poolbeg Pharma PLC

Result of upsized and oversubscribed BookBuild Offer

·      Conditionally raised gross proceeds of £150,000 from the
upsized and oversubscribed BookBuild Offer

·      Total gross proceeds conditionally raised pursuant to the
Fundraising therefore increased to £4.865 million

·      Use of net proceeds from the Fundraising:

o  Phase 2a clinical trial for POLB 001, targeting prevention of cancer
immunotherapy-induced Cytokine Release Syndrome (CRS)

o  Oral GLP-1 proof-of-concept clinical trial

o  Cash runway extended through to 2027

Poolbeg Pharma plc (AIM: POLB, 'Poolbeg Pharma' or the 'Company'), a
clinical-stage biopharmaceutical company focussed on the development of
innovative medicines to address unmet medical needs, announces that, further
to the announcements made on 20 May 2025, regarding the proposed BookBuild
Offer (the "BookBuild Offer Announcement"), and on 22 May 2025, regarding the
increased size of the BookBuild Offer to £150,000, and, following the closing
of the BookBuild Offer on 22 May 2025, 6,000,000 BookBuild Offer Shares will
be issued at 2.5 pence per BookBuild Offer Share, conditionally raising gross
proceeds for the Company of £150,000.

In aggregate, following the closing of the BookBuild Offer, together with the
previously announced Placing and Subscription, the Company has conditionally
raised total gross proceeds of £4.865 million.

The BookBuild Offer was oversubscribed and allocations were therefore made to
shareholders applying the principles of soft pre-emption. Shareholders whose
orders matched or exceeded their soft pre-emptive allowance received 100 per
cent of their allowance, with all orders in excess of the allowance scaled
back equally.

Capitalised terms not defined in this announcement (this "Announcement") have
the meanings given to them in the BookBuild Offer Announcement.

The BookBuild Offer is subject to the passing of certain resolutions at a
general meeting of the Company to be held at the offices of DAC Beachcroft
LLP at The Walbrook Building, 25 Walbrook, London, England, EC4N 8AF, UK at
2.00 p.m. on 23 June 2025  and conditional upon, amongst other things, the
New Ordinary Shares being admitted to trading on the AIM market ("AIM")
operated by London Stock Exchange plc (the "London Stock Exchange")
("Admission").

Admission, settlement and dealings

Application will be made to the London Stock Exchange for the BookBuild Offer
Shares to be admitted to trading on AIM.

Admission is expected to take place at 8.00 a.m. on 25 June 2025 and dealings
in the BookBuild Offer Shares are expected to commence at 8.00 a.m. on 25 June
2025 or, in each case, such later time and/or date as Shore Capital and the
Company agree (being in any event no later than 8.00 a.m. on 23 July 2025).

The BookBuild Offer Shares, when issued, will be credited as fully paid and
will rank pari passu in all respects with the existing Ordinary Shares,
including the right to receive all dividends and other distributions declared,
made or paid after the date of issue.

Total Voting Rights

Following Admission of the 197,200,000 New Ordinary Shares (being the Placing
Shares, the Subscription Shares, the BookBuild Offer Shares and the Fee
Shares), the total issued capital of the Company will consist of 697,200,000
Ordinary Shares with voting rights. The Company does not hold any Ordinary
Shares in treasury. Therefore, the total number of voting rights in the
Company following Admission will be 697,200,000 and this figure may be used by
shareholders in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 Enquiries:
 Poolbeg Pharma Plc                                                          +44 (0) 207 183 1499
 Cathal Friel, Executive Chair                                               ir@poolbegpharma.com
 Jeremy Skillington, CEO
 Ian O'Connell, CFO
 Shore Capital (Sole Broker & Bookrunner in respect of the Fundraising;      +44 (0) 207 408 4090
 Joint Broker to the Company)
 David Coaten, Harry Davies-Ball (Corporate Advisory)

 Malachy McEntyre, Isobel Jones (Corporate Broking)

 Cavendish Capital Markets Ltd (NOMAD & Joint Broker to the Company)         +44 (0) 207 220 0500
 Geoff Nash, Trisyia Jamaludin (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Harriet Ward (ECM)

 J&E Davy (Joint Broker to the Company)                                      +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                            +44 (0) 208 078 4357
 Nick Bastin, Vici Rabbetts, Elena Bates                                     poolbeg@optimumcomms.com

 

About Poolbeg Pharma plc

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on
the development of innovative medicines to address unmet medical needs. The
Company's clinical programmes target large addressable markets including,
cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") and metabolic
conditions such as obesity with the development of an oral encapsulated
glucagon-like peptide receptor (GLP-1R) agonist. For more information, please
go to www.poolbegpharma.com (http://www.poolbegpharma.com/)  or follow us
on X (http://x.com/PoolbegPharma)   (http://x.com/PoolbegPharma)
and LinkedIn (http://www.linkedin.com/company/poolbeg-pharma) .

IMPORTANT NOTICES

 

This announcement has been prepared by, and is the sole responsibility of, the
Company.

This announcement and the information contained herein is not for release,
publication or distribution, directly or indirectly, in whole or in part, in
or into or from the United States of America (including its territories and
possessions, any state of the United States of America and the District of
Columbia (the "United States" or "US")), Australia, Canada, New Zealand,
Japan, the Republic of South Africa, any member state of the EEA or any other
jurisdiction where to do so might constitute a violation of the relevant laws
or regulations of such jurisdiction.

The New Ordinary Shares have not been and will not be registered under the US
Securities Act of 1933, as amended (the "US Securities Act") or under the
applicable state securities laws of the United States and may not be offered
or sold directly or indirectly in or into the United States. No public
offering of the New Ordinary Shares is being made in the United States. The
New Ordinary Shares are being offered and sold outside the United States in
"offshore transactions", as defined in, and in compliance with, Regulation S
under the US Securities Act ("Regulation S") to non-US persons (within the
meaning of Regulation S). In addition, the Company has not been, and will not
be, registered under the US Investment Company Act of 1940, as amended.

This announcement does not constitute an offer to sell or issue or a
solicitation of an offer to buy or subscribe for New Ordinary Shares in the
United States, Australia, Canada, New Zealand, Japan, the Republic of South
Africa, any member state of the EEA or any other jurisdiction in which such
offer or solicitation is or may be unlawful. No public offer of the securities
referred to herein is being made in any such jurisdiction.

This announcement is not for publication or distribution, directly or
indirectly, in or into the United States. This announcement is not an offer of
securities for sale into the United States. The securities referred to herein
have not been and will not be registered under the US Securities Act, and may
not be offered or sold in the United States, except pursuant to an applicable
exemption from registration. No public offering of securities is being made in
the United States.

The value of the New Ordinary Shares and the income from them is not
guaranteed and can fall as well as rise due to stock market movements. When
you sell your investment, you may get back less than you originally invested.
Figures refer to past performance and past performance is not a reliable
indicator of future results. Returns may increase or decrease as a result of
currency fluctuations.

This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg Pharma's present
and future business strategies and the environment in which Poolbeg Pharma
expects to operate in the future. Forward-looking statements involve inherent
known and unknown risks, uncertainties and contingencies because they relate
to events and depend on circumstances that may or may not occur in the future
and may cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg Pharma's ability to control or
estimate precisely, such as future market conditions, currency fluctuations,
the behaviour of other market participants, the outcome of clinical trials,
the actions of regulators and other factors such as Poolbeg Pharma's ability
to obtain financing, changes in the political, social and regulatory framework
in which Poolbeg Pharma operates or in economic, technological or consumer
trends or conditions. Past performance should not be taken as an indication or
guarantee of future results, and no representation or warranty, express or
implied, is made regarding future performance. No person is under any
obligation to update or keep current the information contained in this
announcement or to provide the recipient of it with access to any additional
relevant information.

Neither the content of the Company's website (or any other website) nor the
content of any website accessible from hyperlinks on the Company's website (or
any other website) is incorporated into or forms part of this announcement.
The New Ordinary Shares to be issued or sold pursuant to the BookBuild Offer
will not be admitted to trading on any stock exchange other than the London
Stock Exchange.

Shore Capital Stockbrokers Limited ("SCS") and Shore Capital and Corporate
Limited ("SCC", together with SCS, "Shore Capital"), which are authorised and
regulated in the UK by the Financial Conduct Authority (the "FCA"), are acting
exclusively for the Company in connection with the matters described in this
Announcement and are not acting for any other person in relation to the
matters described in this Announcement. Shore Capital will not be responsible
to anyone other than the Company for providing the protections afforded to
clients of Shore Capital or for advising any other person on the arrangements
described in this Announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIBIGDUDUDDGUD